Sorafenib in Advanced Hepatocellular Carcinoma

Abstract

In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo. (ClinicalTrials.gov number, NCT00105443.)

References

Page 1

	Year	Citations
Global cancer statistics Ahmedin Jemal, Freddie Bray CA A Cancer Journal for Clinicians	2011	55K
Global Cancer Statistics, 2002 Donald Maxwell Parkin, Freddie Bray, Jacques Ferlay, CA A Cancer Journal for Clinicians Epidemiology Of CancerWorldwide IncidenceCancer RegistrationCancer DeathCancer Risk Factors	2005	18.4K
New Guidelines to Evaluate the Response to Treatment in Solid Tumors Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer, JNCI Journal of the National Cancer Institute World Health OrganizationSolid TumorsCancer ManagementMetronomic ChemotherapyResponse Assessment	2000	15.7K
Sorafenib in Advanced Hepatocellular Carcinoma Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro, New England Journal of Medicine	2008	12.8K
Toxicity and response criteria of the Eastern Cooperative Oncology Group Martin M. Oken, Richard H. Creech, Douglass C. Tormey, American Journal of Clinical Oncology Health SciencesMedicineCancer ManagementClinical EndpointPharmacology	1982	11.4K
Transection of the oesophagus for bleeding oesophageal varices R. N. H. Pugh, I M Murray-Lyon, J L Dawson, British journal of surgery VaricesEsophagusHepatologyEmergency LigationPatient Safety	1973	7.9K
Management of Hepatocellular Carcinoma * Jordi Bruix, Morris Sherman Hepatology	2005	5.9K
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Ann‐Lii Cheng, Yoon‐Koo Kang, Zhendong Chen, The Lancet Oncology HepatologyMedicineCancer ManagementPhase IiiClinical Trials	2008	5.8K
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma Bernard Escudier, Tim Eisen, Walter M. Stadler, New England Journal of Medicine	2007	4.8K
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference Jordi Bruix, Morris Sherman, Josep M. Llovet, Journal of Hepatology Clinical ManagementHepatologyBarcelona-2000 Easl ConferenceMedicineHistopathology	2001	4.1K

Page 1